Orforglipron Weight Loss Tablets Explained
Disclaimer
This information is provided for general awareness only. Orforglipron is not licensed in the UK and cannot be prescribed, supplied, or purchased. This page does not constitute advertising or promotion of an unlicensed medicine. Treatment decisions must be made by a qualified prescriber in accordance with UK regulations.
What is orforglipron?
Orforglipron is an oral GLP‑1 receptor agonist currently under investigation for potential use in weight management and type 2 diabetes.
It is being developed by Eli Lilly and is undergoing clinical trials. All information presented here is based on publicly available clinical‑trial data and manufacturer statements.
Orforglipron belongs to a class of medications called GLP-1 receptor agonists. GLP-1 is a natural signal that already exists in your body that tells your stomach you are full, in addition to playing a vital role in regulating blood sugar levels, particularly after meals.
GLP-1 agonists mimic this signal, which helps to:
- slow down digestion
- delay stomach emptying
- suppress your appetite
Unlike some established GLP‑1‑based treatments that are administered by injection, orforglipron is being developed as a small‑molecule, non‑peptide tablet.
The way this molecule is designed allows it to be absorbed through the digestive system. This information reflects research and studies completed by the manufacturer and is not an approved treatment option.
Who may orforglipron be suitable for (if approved)?
While it has not yet been approved and the exact eligibility criteria is not final, current clinical trials relate to patient groups with:
- adults with obesity
- adults who are overweight and also have a weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or heart disease.
Any indication would be dependent on the medicine becoming approved and licensed in the UK.
How is orforglipron going to be taken?
In clinical trials, orforglipron has been administered as a once‑daily tablet. Reported studied trial doses include 6 mg, 12 mg and 36 mg; however, these do not represent approved or recommended dosing, as this information relates to clinical trials.
Clinical trials: results and side effects
From the press release from Eli Lilly here:
Over 40 weeks, patients in clinical trials taking orforglipron pills had an average weight loss of 9.4% to 14.7%. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo.
The most common side effects reported in trials were gastrointestinal issues like nausea, vomiting, constipation and diarrhoea, similar to those experienced with GLP-1 injections. These were generally mild to moderate.
It is important to note that clinical trial data may not indicate real world performance in UK clinical settings.
When can I buy orforglipron in the UK?
This medicine is not currently licensed in the UK and is therefore not available on the UK market
Eli Lilly have stated they plan to submit the final Phase 3 clinical trial data to the FDA by the end of 2025 for weight loss and then in early 2026 for diabetes treatment.
Manufactures indicated timelines discuss that the medication could be on the market in the first half of 2026. However, UK availability is uncertain and dependent on MHRA review and approval. Even if approved in other countries, UK licensing may differ.
Are there alternative treatments available?
Orforglipron is undergoing clinical trials and is not yet licensed in the UK, online services that are offering this are not safe and should be considered a risk.
If you are looking for licensed weight loss medication, there are treatments that could be suitable for you following a consultation.
Mounjaro and Wegovy are once-weekly, pre-filled injection pens, approved by the MHRA for weight loss.
To be eligible for either of these from Chemist4U, you must be 18 years or older and:
- be medically obese (have a BMI of over 30)
- or be overweight with weight-related issues (a BMI of over 27 and a condition like: high cholesterol, high blood pressure, or type 2 diabetes)
Your consultation will be reviewed by one of our GPHC-registered prescribing clinicians, and if you are eligible, you may be able to receive them from our online service.
Frequently asked questions about orforglipron
Is orforglipron injected?
Clinical trials have specifically tested orforglipron as an oral tablet, as opposed to via injection route. However findings only relate to clinical trial information only, and do not indicate future suitability.
How much will orforglipron cost?
It’s not yet known how much orforglipron will cost in the UK as it has not yet been released to the market. It will need to be approved by regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) first.
